FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
June 9, 2025
Foley Viewpoints
New Disclosure Requirements for Florida Resorts and Food Establishments
Described as a law to make it easier to remove hotel guests who have not paid their bills, Florida Bill SB 606 (“the Bill”) includes…
June 9, 2025
Foley Viewpoints
Franchise Agreement Requiring Out of State Mediation Is Unenforceable in California Background
Dispute resolution provisions in franchise agreements often address how, when, and where parties will mediate. However, the…
May 29, 2025
Foley Viewpoints
Keep Wining: Franchise Statute Opens Door to Protections for Missouri Wine Distributor
The Eighth Circuit recently applied a novel, broad reading of the Missouri Franchise Act granting franchise protection to distributors…